title: Concern about the use of venlafaxine to treat vasomotor symptoms--reply.
authors.affiliation: Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts2Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts3Massachusetts General Hospital, Harvard Medical School, Boston.
authors.forename: Hadine
authors.initials: H
authors.lastname: Joffe
authors.affiliation: MsFLASH Data Coordinating Center, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington5Department of Family and Preventative Medicine, University of California, San Diego.
authors.forename: Andrea Z
authors.initials: AZ
authors.lastname: LaCroix
authors.affiliation: Massachusetts General Hospital, Harvard Medical School, Boston.
authors.forename: Lee
authors.initials: L
authors.lastname: Cohen
mesh_terms: D003511:Cyclohexanols / Q000627:therapeutic use*; D004958:Estradiol / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy; D005260:Female; D019584:Hot Flashes / Q000188:drug therapy*; D006801:Humans; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*
chemical_list: D003511:Cyclohexanols; D004958:Estradiol; D017367:Selective Serotonin Reuptake Inhibitors